The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a “classical” strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an “optimized” strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary.
R. Corre
No relevant relationships to disclose
C. Chouaid
Consultant or Advisory Role - Amgen; Lilly; Roche
Honoraria - Amgen; GlaxoSmithKline; Lilly; Roche
Research Funding - Amgen; Roche
F. Barlesi
Consultant or Advisory Role - Roche
Research Funding - Roche
H. Le Caer
Honoraria - Lilly
E. Dansin
Honoraria - Lilly; Roche
A. Vergnenegre
Honoraria - AstraZeneca; Lilly; Roche
P. Fournel
Honoraria - Lilly; Roche